Century Therapeutics, Inc.
IPSC Healthcare Biotechnology
Century Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $109.2 million, up 1,556.8% from fiscal 2024. In the quarter to June 2026, revenue grew 12,667.7%, EPS grew 55.3% and free cash flow grew 26.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow IPSC
Century Therapeutics, Inc. (IPSC) EV/Sales
As of 16 October 2026, Century Therapeutics, Inc. (IPSC) trades at a EV/Sales of 1.4×. Over the past ten years it has ranged from −42.2× (December 2024) to 64.2× (March 2024); the current reading is higher than 80% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.3× | — |
| FY2024 | −16.7× | — |
| FY2023 | 19.6× | — |
| FY2022 | −3.2× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Mar 2025 | −1.1× | — |
| Dec 2024 | −16.7× | — |
| Sep 2024 | −19.8× | — |
| Jun 2024 | 0.9× | (98.00%) |
| 9 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| FULC Fulcrum Therapeutics, Inc. compare | −0.5× |
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. | 1.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.6× |
| PRLD Prelude Therapeutics Incorporated compare | 7.5× |
| OCGN Ocugen, Inc. compare | 36.2× |
| EYPT EyePoint, Inc. compare | 40.8× |
| PALI Palisade Bio, Inc. compare | 230× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)